The enrolled population in 17 trials included patients with type 2 diabetes mellitus [3, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 30, 32], whereas seven studies assessed the efficacy of GLP‐1 agonists in overweight/obese patients without diabetes [8, 15, 28, 31, 33, 34, 35]. Here, GLP1R is linked to diabetes mellitus.